| 摘要 |
The invention relates to the use of lornoxicam or analogues thereof which inhibit cyclo--oxygenase 1 and cyclo-oxygenase 2 (COX 1 and COX 2), cannot penetrate the blood--brain barrier under physiological conditions, and reduce the prostaglandin E2-induced induction of the amyloid-precursor-protein (APP), for producing a pharmaceutical composition for the treatment or prevention of Alzheimer's disease or arteriosclerosis.
|
